GSK/Corixa Bexxar User Fee Deadline Extended To Review Safety Database
Executive Summary
FDA is extending GSK/Corixa's Bexxar user fee deadline by three months to review additional safety information on the radioimmunotherapy
You may also be interested in...
GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval
GlaxoSmithKline and Corixa's Bexxar nuclear pharmacy training program could help encourage faster uptake of the oncologic than Idec's Zevalin
GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval
GlaxoSmithKline and Corixa's Bexxar nuclear pharmacy training program could help encourage faster uptake of the oncologic than Idec's Zevalin
Erbitux BLA Resubmission Plan Set; Will Test Accelerated Approval Rules
Bristol and ImClone will take advantage of FDA's new accelerated approval interpretation in resubmitting the BLA for the oncology agent Erbitux